Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

566 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Real-World Effectiveness of Vedolizumab vs Anti-TNF in Biologic-naïve Crohn's Disease Patients: A 2-year Propensity-score-adjusted Analysis from the VEDOIBD-Study.
Bokemeyer B, Plachta-Danielzik S, di Giuseppe R, Efken P, Mohl W, Hoffstadt M, Krause T, Schweitzer A, Schnoy E, Atreya R, Teich N, Trentmann L, Ehehalt R, Hartmann P, Schreiber S. Bokemeyer B, et al. Among authors: krause t. Inflamm Bowel Dis. 2024 May 2;30(5):746-756. doi: 10.1093/ibd/izad138. Inflamm Bowel Dis. 2024. PMID: 37523666
Real-world Comparative Effectiveness of Ustekinumab vs Anti-TNF in Crohn's Disease With Propensity Score Adjustment: Induction Phase Results From the Prospective, Observational RUN-CD Study.
Bokemeyer B, Plachta-Danielzik S, di Giuseppe R, Mohl W, Teich N, Hoffstadt M, Schweitzer A, von der Ohe M, Gauss A, Atreya R, Krause T, Blumenstein I, Hartmann P, Schreiber S. Bokemeyer B, et al. Among authors: krause t. Inflamm Bowel Dis. 2023 Nov 2;29(11):1741-1750. doi: 10.1093/ibd/izac271. Inflamm Bowel Dis. 2023. PMID: 36633301
Real-world effectiveness of vedolizumab compared to anti-TNF agents in biologic-naïve patients with ulcerative colitis: A two-year propensity-score-adjusted analysis from the prospective, observational VEDOIBD -study.
Bokemeyer B, Plachta-Danielzik S, di Giuseppe R, Efken P, Mohl W, Krause T, Hoffstadt M, Ehehalt R, Trentmann L, Schweitzer A, Jessen P, Hartmann P, Schreiber S. Bokemeyer B, et al. Among authors: krause t. Aliment Pharmacol Ther. 2023 Aug;58(4):429-442. doi: 10.1111/apt.17616. Epub 2023 Jun 15. Aliment Pharmacol Ther. 2023. PMID: 37322825
Electronic Nudge Letters to Increase Influenza Vaccination Uptake in Younger and Middle-Aged Individuals With Diabetes.
Lassen MCH, Johansen ND, Vaduganathan M, Bhatt AS, Modin D, Chatur S, Claggett BL, Janstrup KH, Larsen CS, Larsen L, Wiese L, Dalager-Pedersen M, Køber L, Solomon SD, Sivapalan P, Jensen JUS, Martel CJ, Krause TG, Biering-Sørensen T. Lassen MCH, et al. Among authors: krause tg. JACC Adv. 2024 Nov 13;3(12):101391. doi: 10.1016/j.jacadv.2024.101391. eCollection 2024 Dec. JACC Adv. 2024. PMID: 39606218 Free PMC article.
Evaluating the effect of BCG vaccination for non-specific protection from infection in senior citizens during the COVID-19 pandemic: A randomised clinical trial.
Madsen AMR, Gehrt L, Schaltz-Buchholzer F, Möller S, Christiansen R, Schellerup L, Norberg LA, Krause TG, Nielsen S, Bliddal M, Aaby P, Benn CS. Madsen AMR, et al. Among authors: krause tg. J Infect. 2024 Oct 17;89(6):106319. doi: 10.1016/j.jinf.2024.106319. Online ahead of print. J Infect. 2024. PMID: 39423874 Free article.
Electronic Nudges to Increase Influenza Vaccination in Patients With Chronic Diseases: A Randomized Clinical Trial.
Johansen ND, Vaduganathan M, Bhatt AS, Modin D, Chatur S, Claggett BL, Janstrup KH, Larsen CS, Larsen L, Wiese L, Dalager-Pedersen M, Køber L, Solomon SD, Sivapalan P, Jensen JUS, Martel CJ, Krause TG, Biering-Sørensen T. Johansen ND, et al. Among authors: krause tg. JAMA. 2024 Oct 11:e2421060. doi: 10.1001/jama.2024.21060. Online ahead of print. JAMA. 2024. PMID: 39392741
Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial.
Fong Y, Dang L, Zhang B, Fintzi J, Chen S, Wang J, Rouphael NG, Branche AR, Diemert DJ, Falsey AR, Losada C, Baden LR, Frey SE, Whitaker JA, Little SJ, Kamidani S, Walter EB, Novak RM, Rupp R, Jackson LA, Yu C, Magaret CA, Molitor C, Borate B, Babu TM, Kottkamp AC, Luetkemeyer AF, Immergluck LC, Presti RM, Bäcker M, Winokur PL, Mahgoub SM, Goepfert PA, Fusco DN, Atmar RL, Posavad CM, Mu J, Makowski M, Makhene MK, Nayak SU, Roberts PC, Follmann D, Gilbert PB; Coronavirus Variant Immunologic Landscape Trial (COVAIL) Study Team. Fong Y, et al. Clin Infect Dis. 2024 Sep 26:ciae465. doi: 10.1093/cid/ciae465. Online ahead of print. Clin Infect Dis. 2024. PMID: 39325506
566 results